Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
- PMID: 24442145
- DOI: 10.1038/nrc3648
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Abstract
The neuroendocrine tumours pheochromocytomas and paragangliomas carry the highest degree of heritability in human neoplasms, enabling genetic alterations to be traced to clinical phenotypes through their transmission in families. Mutations in more than a dozen distinct susceptibility genes have implicated multiple pathways in these tumours, offering insights into kinase downstream signalling interactions and hypoxia regulation, and uncovering links between metabolism, epigenetic remodelling and cell growth. These advances extend to co-occurring tumours, including renal, thyroid and gastrointestinal malignancies. Hereditary pheochromocytomas and paragangliomas are powerful models for recognizing cancer driver events, which can be harnessed for diagnostic purposes and for guiding the future development of targeted therapies.
Similar articles
-
Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.Adv Anat Pathol. 2015 Sep;22(5):283-93. doi: 10.1097/PAP.0000000000000086. Adv Anat Pathol. 2015. PMID: 26262510 Review.
-
[Diagnostic approach of pheochromocytomas and paragangliomas].Hipertens Riesgo Vasc. 2019 Jan-Mar;36(1):34-43. doi: 10.1016/j.hipert.2018.06.003. Epub 2018 Aug 2. Hipertens Riesgo Vasc. 2019. PMID: 30078655 Spanish.
-
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.Cytogenet Genome Res. 2016;150(3-4):227-241. doi: 10.1159/000457479. Epub 2017 Feb 24. Cytogenet Genome Res. 2016. PMID: 28231563 Review.
-
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.Endocr Relat Cancer. 2013 May 21;20(3):349-59. doi: 10.1530/ERC-13-0101. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23533246 Free PMC article.
-
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101416. doi: 10.1016/j.beem.2020.101416. Epub 2020 Mar 10. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32295730 Review.
Cited by
-
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.Genes Chromosomes Cancer. 2015 Sep;54(9):542-54. doi: 10.1002/gcc.22267. Epub 2015 May 29. Genes Chromosomes Cancer. 2015. PMID: 26032282 Free PMC article.
-
Harnessing hypoxia as an evolutionary driver of complex multicellularity.Interface Focus. 2020 Aug 6;10(4):20190101. doi: 10.1098/rsfs.2019.0101. Epub 2020 Jun 12. Interface Focus. 2020. PMID: 32642048 Free PMC article.
-
Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.J Clin Endocrinol Metab. 2015 Apr;100(4):1325-34. doi: 10.1210/jc.2014-3863. Epub 2015 Jan 12. J Clin Endocrinol Metab. 2015. PMID: 25581599 Free PMC article.
-
Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics. 2024 Jan 1;14(1):17-32. doi: 10.7150/thno.87345. eCollection 2024. Theranostics. 2024. PMID: 38164150 Free PMC article. Review.
-
Molecular classification and tumor microenvironment characteristics in pheochromocytomas.Elife. 2024 Feb 26;12:RP87586. doi: 10.7554/eLife.87586. Elife. 2024. PMID: 38407266 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical